Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion
- Sponsor
- Nagoya City University
- Study ID
- NCT02478515
- Phase
- PHASE4
- Status
- Completed
Conditions
- Branch Retinal Vein Occlusion
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ranibizumab — DRUGIntraviteal injection of 0.5mg ranibizumab
Study Details
Monthly intravitreal ranibizumab (IVR) during the first 6 month had great effect for macular edema with branch retinal vein occlusion (BVO) both in visual and anatomical outcome. It is expected that similar results could be obtained by less frequent IVR. The purpose of this study is to investigate if IVR by PRN is as effective as by monthly. In addition, the investigators are going to study the relationship between macular edema and the size and location of retinal non-perfusion area.
Key Dates
- First listed
- Jun 23, 2015
- Start date
- Jan 31, 2014
- Status verified
- Oct 2016
- Primary completion
- Mar 31, 2019
- Completion
- Mar 31, 2019
Study Design
- Enrollment
- 27 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Intraviteal Ranibizumab 0.5mgIntraviteal Ranibizumab 0.5mg
Primary Outcome Measure
Visual acuity [ Time Frame: One years ]